Growth Metrics

Pfizer (PFE) Current Deferred Tax Assets (2016 - 2025)

Historic Current Deferred Tax Assets for Pfizer (PFE) over the last 16 years, with Q3 2025 value amounting to $3.9 billion.

  • Pfizer's Current Deferred Tax Assets rose 1887.14% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 1887.14%. This contributed to the annual value of $3.3 billion for FY2024, which is 1669.18% down from last year.
  • As of Q3 2025, Pfizer's Current Deferred Tax Assets stood at $3.9 billion, which was up 1887.14% from $4.0 billion recorded in Q2 2025.
  • Pfizer's 5-year Current Deferred Tax Assets high stood at $4.3 billion for Q4 2021, and its period low was $2.5 billion during Q4 2022.
  • Over the past 5 years, Pfizer's median Current Deferred Tax Assets value was $3.6 billion (recorded in 2022), while the average stood at $3.5 billion.
  • In the last 5 years, Pfizer's Current Deferred Tax Assets crashed by 3438.23% in 2022 and then skyrocketed by 5397.01% in 2023.
  • Over the past 5 years, Pfizer's Current Deferred Tax Assets (Quarter) stood at $4.3 billion in 2021, then decreased by 16.15% to $3.6 billion in 2022, then rose by 11.21% to $4.0 billion in 2023, then fell by 16.69% to $3.3 billion in 2024, then grew by 16.32% to $3.9 billion in 2025.
  • Its Current Deferred Tax Assets was $3.9 billion in Q3 2025, compared to $4.0 billion in Q2 2025 and $2.9 billion in Q1 2025.